Liminal Biosciences (NASDAQ:LMNL) will report on Q4 2022.
ADHD Medication Shortage Worsens, Vyvanse Supply Dwindles Amid Adderall Scarcity
The supply of an alternative to Adderall, Vyvanse (lisdexamfetamine), a commonly used medication for Attention-deficit/hyperactivity disorder (ADHD), is dwindling, further limiting options for patients in the U.S. who have been facing a nationwide shortage of ADHD drugs for nearly a year.
